Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
Titel:
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
Auteur:
Yau, Thomas Kaseb, Ahmed Cheng, Ann-Lii Qin, Shukui Zhu, Andrew X Chan, Stephen L Melkadze, Tamar Sukeepaisarnjaroen, Wattana Breder, Valery Verset, Gontran Gane, Edward Borbath, Ivan Rangel, Jose David Gomez Ryoo, Baek-Yeol Makharadze, Tamta Merle, Philippe Benzaghou, Fawzi Milwee, Steven Wang, Zhong Curran, Dominic Kelley, Robin Kate Rimassa, Lorenza